Last reviewed · How we verify
Sitagliptin phosphate anhydrous formulation — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Sitagliptin phosphate anhydrous formulation (Sitagliptin phosphate anhydrous formulation) — Merck Sharp & Dohme LLC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Sitagliptin phosphate anhydrous formulation TARGET | Sitagliptin phosphate anhydrous formulation | Merck Sharp & Dohme LLC | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Sitagliptin phosphate anhydrous formulation CI watch — RSS
- Sitagliptin phosphate anhydrous formulation CI watch — Atom
- Sitagliptin phosphate anhydrous formulation CI watch — JSON
- Sitagliptin phosphate anhydrous formulation alone — RSS
Cite this brief
Drug Landscape (2026). Sitagliptin phosphate anhydrous formulation — Competitive Intelligence Brief. https://druglandscape.com/ci/sitagliptin-phosphate-anhydrous-formulation. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab